NHS Scotland, AZ and Scottish universities partner for kidney health research
The collaboration aims to develop new medicines to reduce chronic kidney disease in Scotland
Read Moreby Jen Brogan | Aug 1, 2024 | News | 0
The collaboration aims to develop new medicines to reduce chronic kidney disease in Scotland
Read Moreby Jen Brogan | Jul 9, 2024 | News | 0
The serious, progressive kidney disease affects nearly 850 million people worldwide
Read Moreby Jen Brogan | Oct 11, 2023 | News | 0
Eligible patients in Scotland will now have access to Nubeqa and Stivarga
Read Moreby John Pinching | May 10, 2023 | News | 0
Patients living with the debilitating impacts of migraine attacks will be able to access Vydura
Read Moreby John Pinching | Aug 18, 2022 | News | 0
The SMC approval brings much-needed boost to asthma sufferers across Scotland
Read Moreby Lucy Parsons | Feb 9, 2021 | News | 0
BMS’ MS therapy Zeposia and AbbVie’s JAK inhibitor Rinvoq among latest approvals
Read Moreby Lucy Parsons | Jan 19, 2021 | News | 0
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Read Moreby Selina McKee | Dec 8, 2020 | News | 0
Medicines for blood cancer and a rare muscle disorder will be made available for NHS patients
Read Moreby Lucy Parsons | Nov 10, 2020 | News | 0
Akcea’s Waylivra approved via ultra-orphan pathway
Read Moreby Anna Smith | Jul 9, 2019 | News | 0
The Scottish Medicines Consortium (SMC) has announced its latest round of decisions for NHS Scotland, publishing advice accepting three new medicines.
Read Moreby Anna Smith | Apr 9, 2019 | News | 0
Also mentioned were Eisai and MSD’s Lenvima and UCB’s Cimzia.
Read Moreby Selina McKee | Dec 10, 2018 | News | 0
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
